Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Clinical trial NCT05580588 · TERMINATED
Trial details
- NCT number
- NCT05580588
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-31
- Primary completion
- 2024-10-04
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.